Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease
NCT03408015Phase 4Withdrawn
- Sponsor
- University of Alabama at Birmingham
- Start
- Jan 2019
- Primary completion
- Jan 2019
01
Overview
Phase 4, open-label trial of lifitegrast in dry eye syndrome (DED) and keratoconjunctivitis sicca (KCS) (3 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: Total number of T cells recovered from the closed eye at 84 days. Planned start Jan 2019; status: withdrawn.
02
Drugs
lifitegrast
03
Conditions
dry eye syndrome (DED)keratoconjunctivitis sicca (KCS)
Beyond the preview
Go deeper on NCT03408015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03408015.